Advertisement
Screener

Orchestra BioMed Holdings, Inc. (OBIO) Increase (Decrease) in Contract with Customer, Liability

2.8 / 5 stars · 68/120 Roast Me

Orchestra BioMed Holdings, Inc. Increase (Decrease) in Contract with Customer, Liability

Orchestra BioMed Holdings, Inc. (OBIO) reported Increase (Decrease) in Contract with Customer, Liability of -$15.43 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-10

  • Orchestra BioMed Holdings, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was -$13.31M.
  • Orchestra BioMed Holdings, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was -$721.00K.
  • Orchestra BioMed Holdings, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-06-30 was -$667.00K.
  • Orchestra BioMed Holdings, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-03-31 was -$732.00K.
  • Orchestra BioMed Holdings, Inc. increase (decrease) in contract with customer, liability for fiscal 2025 was -$15.43M.
  • Orchestra BioMed Holdings, Inc. increase (decrease) in contract with customer, liability for fiscal 2024 was -$2.00M.
  • Orchestra BioMed Holdings, Inc. increase (decrease) in contract with customer, liability for fiscal 2023 was -$2.11M.
  • Orchestra BioMed Holdings, Inc. increase (decrease) in contract with customer, liability for fiscal 2022 was -$2.86M.
Period endIncrease (Decrease) in Contract with Customer, Liability 3 monthIncrease (Decrease) in Contract with Customer, Liability 6 monthIncrease (Decrease) in Contract with Customer, Liability 9 monthIncrease (Decrease) in Contract with Customer, Liability 12 month
2025-12-31-$13.31M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12
-$14.03M
derived: sum of 2 quarters · filed 2026-03-12
-$14.70M
derived: sum of 3 quarters · filed 2026-08-10
-$15.43M
10-K · filed 2026-03-12
2025-09-30-$721.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10
-$1.39M
derived: sum of 2 quarters · filed 2026-08-10
-$2.12M
10-Q · filed 2025-11-10
-$2.20M
derived: sum of 4 quarters · filed 2026-08-10
2025-06-30-$667.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10
-$1.40M
10-Q · filed 2026-08-10
-$1.48M
derived: sum of 3 quarters · filed 2026-08-10
-$2.28M
derived: sum of 4 quarters · filed 2026-08-10
2025-03-31-$732.00K
10-Q · filed 2026-05-12
-$809.00K
derived: sum of 2 quarters · filed 2026-05-12
-$1.61M
derived: sum of 3 quarters · filed 2026-05-12
-$2.24M
derived: sum of 4 quarters · filed 2026-05-12
2024-12-31-$77.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12
-$880.00K
derived: sum of 2 quarters · filed 2026-03-12
-$1.51M
derived: sum of 3 quarters · filed 2026-03-12
-$2.00M
10-K · filed 2026-03-12
2024-09-30-$803.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10
-$1.43M
derived: sum of 2 quarters · filed 2025-11-10
-$1.93M
10-Q · filed 2025-11-10
-$2.02M
derived: sum of 4 quarters · filed 2025-11-10
2024-06-30-$628.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12
-$1.13M
10-Q · filed 2025-08-12
-$1.21M
derived: sum of 3 quarters · filed 2025-08-12
-$1.48M
derived: sum of 4 quarters · filed 2025-08-12
2024-03-31-$497.00K
10-Q · filed 2025-05-12
-$585.00K
derived: sum of 2 quarters · filed 2025-05-12
-$856.00K
derived: sum of 3 quarters · filed 2025-05-12
-$1.58M
derived: sum of 4 quarters · filed 2025-05-12
2023-12-31-$88.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31
-$359.00K
derived: sum of 2 quarters · filed 2025-03-31
-$1.09M
derived: sum of 3 quarters · filed 2025-03-31
-$2.11M
10-K · filed 2025-03-31
2023-09-30-$271.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12
-$999.00K
derived: sum of 2 quarters · filed 2024-11-12
-$2.02M
10-Q · filed 2024-11-12
-$2.95M
derived: sum of 4 quarters · filed 2024-11-12
2023-06-30-$728.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12
-$1.75M
10-Q · filed 2024-08-12
-$2.68M
derived: sum of 3 quarters · filed 2024-08-12
-$3.66M
derived: sum of 4 quarters · filed 2024-08-12
2023-03-31-$1.02M
10-Q · filed 2024-05-13
-$1.95M
derived: sum of 2 quarters · filed 2024-05-13
-$2.94M
derived: sum of 3 quarters · filed 2024-05-13
-$3.17M
derived: sum of 4 quarters · filed 2024-05-13
2022-12-31-$931.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27
-$1.92M
derived: sum of 2 quarters · filed 2024-03-27
-$2.15M
derived: sum of 3 quarters · filed 2024-03-27
-$2.86M
10-K · filed 2024-03-27
2022-09-30-$986.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13
-$1.22M
derived: sum of 2 quarters · filed 2023-11-13
-$1.93M
10-Q · filed 2023-11-13
2022-06-30-$229.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10
-$945.00K
10-Q · filed 2023-08-10
2022-03-31-$716.00K
10-Q · filed 2023-05-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
SHOULDER INNOVATIONS, INC. (SI)United States$0.355B
Orthofix Medical Inc. (OFIX)$0.373B
Embecta Corp. (EMBC)United States$0.319B2.10
CARLSMED, INC. (CARL)United States$0.405B
TREACE MEDICAL CONCEPTS, INC. (TMCI)United States$0.297B-4.32
Mobia Medical, Inc. (MOBI)United States$0.293B
TriSalus Life Sciences, Inc. (TLSI)United States$0.283B-9.92
Cytosorbents Corp (CTSO)United States$0.274B-1.29
ORASURE TECHNOLOGIES INC (OSUR)United States$0.272B-6.26
Anika Therapeutics, Inc. (ANIK)United States$0.272B-51.71